Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Florensocatib - Haisco Pharmaceutical Group

Next Previous
Drug Profile

Florensocatib - Haisco Pharmaceutical Group

Alternative Names: CHF-10196; HSK-31858

Latest Information Update: 11 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Haisco Pharmaceutical Group
  • Class Amides; Antiasthmatics; Antibronchitics; Benzoxazoles; Fluorobenzenes; Ketones; Nitriles; Oxazepines; Small molecules
  • Mechanism of Action Cathepsin C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bronchiectasis
  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 11 Aug 2026 Chiesi Farmaceutici plans a phase I drug-drug interaction trial (In Volunteers) in United Kingdom (PO) in October 2026 (NCT07744386)
  • 06 Jul 2026 Chiesi Farmaceutici plans a phase I pharmacokinetic trial in Healthy volunteers in United Kingdom (NCT07683793)
  • 11 May 2026 Chiesi Farmaceutici plans the phase III FABLE trial in Bronchiectasis (In adolescents, In adults, In the elderly) (PO, Tablet) in November 2026 (NCT07577804)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top